Cantor Fitzgerald analyst Brandon Folkes reiterated an Overweight rating and $6 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) saying a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE